Quoin制药公司在新西兰对儿科PSS病人的QRX003乳液进行了临床试验。 Quoin Pharmaceuticals initiates a clinical trial in New Zealand for QRX003 lotion in pediatric PSS patients.

Quoin制药公司开始在新西兰进行临床研究,以评价其针对皮革皮肤综合症(PSS)的儿科病人的热液(QRX003)。 Quoin Pharmaceuticals begins a clinical study in New Zealand to evaluate its topical lotion, QRX003, for pediatric patients with Peeling Skin Syndrome (PSS). 乳液针对皮肤炎症和屏障干扰,为一种罕见的遗传疾病提供潜在治疗,但没有经批准的治疗方法。 The lotion targets skin inflammation and barrier disruption, offering a potential treatment for a rare genetic disease with no approved cures. Quoin的战略是扩大对各种罕见和孤儿疾病症状的QRX003的临床检测。 Quoin's strategy involves expanding clinical testing for QRX003 in various rare and orphan disease indications.